Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644928 | 0.83 | CYP3A4 (0.47) | GRM2CYP3A4MYC | |
| SCHEMBL12771452 | 0.79 | GRM2 (0.41) | LTA4HGRM2PARP14CYP1A2CYP3A4 | |
| SCHEMBL10157014 | 0.78 | MAOB (0.56) | MAOBLMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10157086 | 0.77 | KIT (0.46) | LTA4HMAOBKDM4ELMNACYP1A2 | |
| SCHEMBL1644426 | 0.77 | POLB (0.58) | GRM2KDM4EPOLBNPSR1 | |
| SCHEMBL6244474 | 0.76 | LOXL2 (0.46) | GRM2PARP14KDM4ECYP3A4MYC | |
| SCHEMBL451725 | 0.76 | MYC (0.39) | GRM2PARP14MYCPRMT5WDR77 | |
| SCHEMBL454924 | 0.76 | RECQL (0.52) | GRM2PARP14MYCPRMT5WDR77 | |
| SCHEMBL3302943 | 0.76 | NOS3 (0.52) | GRM2PARP14CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2642689 | 0.76 | MYC (0.39) | GRM2PARP14MYCPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200040025-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| US-20200040025-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| EP-3515447-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | Tufts University (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018058148-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018058148-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | ZHUANG LINGHANG (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1333831-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2003-07-31 | — | — | US | disclosed |
| US-6534522-B2 | E.g.,N-((4-amino-3-nitrophenoxy)ethyl)-1,2,3,4-tetrahydro -isoquinoline; stroke; antiischemic agents; CNS trauma, hyperglycemic agents; surgery; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis | WARNER-LAMBERT COMPANY | 2003-03-18 | — | — | US | disclosed |
| WO-2002036734-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2001-12-13 | — | — | US | disclosed |
| US-6218404-B1 | THERAPY AND PROPHYLAXIS OF NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CNS TRAUMA, HYPOGLYCEMIA AND SURGERY, NEURO-DEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE | WARNER-LAMBERT CO. | 2001-04-17 | — | — | US | disclosed |
| WO-1997023458-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| US-4112100-A | INCREASING THE ENDOGENOUS PRODUCTION OF PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4088766-A | PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4069224-A | N-(PYRIDYLALKYL)BENZAMIDES, IMPROVE PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-01-17 | — | — | US | disclosed |
| US-4008326-A | INCREASING PRODUCTION OF PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-4001256-A | PROSTAGLANDIN PRODUCTION IN MAMMALS | THE UPJOHN COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | CALM1 1094/4885LTA4H 2820/4885MAOB 2568/4885 |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | CALM1 1094/4885LTA4H 2820/4885MAOB 2568/4885 |
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | POLI, CYP51A1, DUT | CALM1 4584/4885LTA4H 2294/4885MAOB 1816/4885 |
| US-20200040025-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | CALM1 1612/4885LTA4H 1280/4885MAOB 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.